Oliveira M, Pominchuk D, Nowecki Z, Hamilton E, et al. Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial. Lancet Oncol 2024;25:1424-1439.
PMID: 39481395